Brilinta has an FDA Boxed Warning regarding the risk of significant and potentially fatal bleeding. Brilinta should not be administered to patients with active pathological bleeding or a history of bleeding in the brain. In addition, Brilinta should not be administered to patients undergoing urgent coronary artery bypass graft surgery (CABG). If bleeding occurs, it is recommended to be managed without stopping Brilinta, if possible; stopping Brilinta can increase the risk of cardiovascular events. Brilinta also has an FDA Boxed Warning against taking 100 mg or more of aspirin with Brilinta, as doing so can decrease Brilinta's effects. Before you begin treatment with Brilinta, talk to your doctor about:, All the prescription and over-the-counter medications you take, including herbals, vitamins, and supplements., Your allergies., Your current health problems and past medical history., If you are pregnant or breastfeeding., Shortness of breath may occur with the use of Brilinta., Patients should not stop taking Brilinta unless their doctor has instructed them to do so., Abnormal slow heart rhythms can occur with the use of Brilinta., Patients with severe liver problems should not take Brilinta., Central sleep apnea can occur with the use of Brilinta., Brilinta can interfere with certain laboratory tests. All the prescription and over-the-counter medications you take, including herbals, vitamins, and supplements., Your allergies., Your current health problems and past medical history., If you are pregnant or breastfeeding.
